An early-phase, dose-escalation study of a hypofractionated approach to concurrent chemoradiation using an an adaptive stereotactic ablative radiotherapy (SABR) boost showed promising results in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback